Literature DB >> 7984063

In vitro and in vivo 13C and 31P NMR analyses of phosphocholine metabolism in rat glioma cells.

R J Gillies1, J A Barry, B D Ross.   

Abstract

In vivo magnetic resonance spectroscopy (MRS) has revealed that phosphomonoesters (PME) such as phosphocholine (PCho) and phosphoethanolamine (PEth) are elevated in tumors and rapidly proliferating tissues. The regulation of PME levels and their relationship to proliferation are not well known. In the present study, we investigated the regulation of PCho and PEth levels in rat glioma cells grown in vivo and in vitro using 31P and 13C MRS. However, the ability of cells to produce choline endogenously is variable. To fully understand regulation of PCho levels, it is necessary to characterize the activity of the endogenous pathway, if it exists. This was first investigated by following the metabolic fate of 13C-labeled methionine of 9L glioma tumors in vivo. Our results indicate that there is a significant amount of de novo choline synthesis in vivo. However, similar experiments performed in vitro using cells cultured in bioreactors indicated that glioma cells themselves are unable to synthesize choline de novo, suggesting that the in vivo results were due to the involvement of extra-tumoral organs, e.g., liver. Further in vitro experiments demonstrated that the uptake and phosphorylation of physiologically relevant concentrations of exogenous choline is very active in these systems. Thus, it appears that the exogenous pathway for PCho biosynthesis predominates and regulates PCho levels in glioma cells. Our results also demonstrate that PCho levels are lowest, and PEth levels are highest, in non-proliferating cells. These observations indicate that there is a decrease in the biosynthesis of PCho concomitant with a reduction in culture growth. The source of the increased PEth is, as yet, undefined.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7984063     DOI: 10.1002/mrm.1910320306

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  14 in total

Review 1.  Imaging of neurogenetic and neurometabolic disorders of childhood.

Authors:  Andrea Gropman
Journal:  Curr Neurol Neurosci Rep       Date:  2004-03       Impact factor: 5.081

2.  Alterations in cellular metabolome after pharmacological inhibition of Notch in glioblastoma cells.

Authors:  Ulf D Kahlert; Menglin Cheng; Katharina Koch; Luigi Marchionni; Xing Fan; Eric H Raabe; Jarek Maciaczyk; Kristine Glunde; Charles G Eberhart
Journal:  Int J Cancer       Date:  2015-10-13       Impact factor: 7.396

Review 3.  Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy.

Authors:  Siver Andreas Moestue; Olav Engebraaten; Ingrid Susann Gribbestad
Journal:  Mol Oncol       Date:  2011-04-23       Impact factor: 6.603

4.  Proton MRS imaging in pediatric brain tumors.

Authors:  Maria Zarifi; A Aria Tzika
Journal:  Pediatr Radiol       Date:  2016-05-27

Review 5.  MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer.

Authors:  Kristine Glunde; Lu Jiang; Siver A Moestue; Ingrid S Gribbestad
Journal:  NMR Biomed       Date:  2011-07       Impact factor: 4.044

6.  Heterogeneity in malignant gliomas: a magnetic resonance analysis of spatial distribution of metabolite changes and regional blood volume.

Authors:  Marlies Wagner; Reinhold Nafe; Alina Jurcoane; Ulrich Pilatus; Kea Franz; Johannes Rieger; Joachim P Steinbach; Elke Hattingen
Journal:  J Neurooncol       Date:  2011-07       Impact factor: 4.130

7.  Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study.

Authors:  Elke Hattingen; Alina Jurcoane; Oliver Bähr; Johannes Rieger; Jörg Magerkurth; Sandra Anti; Joachim P Steinbach; Ulrich Pilatus
Journal:  Neuro Oncol       Date:  2011-09-02       Impact factor: 12.300

8.  Prognostic value of choline and creatine in WHO grade II gliomas.

Authors:  Elke Hattingen; Peter Raab; Kea Franz; Heiner Lanfermann; Matthias Setzer; Rüdiger Gerlach; Friedhelm E Zanella; Ulrich Pilatus
Journal:  Neuroradiology       Date:  2008-06-04       Impact factor: 2.804

Review 9.  Choline kinase alpha-Putting the ChoK-hold on tumor metabolism.

Authors:  Sean P Arlauckas; Anatoliy V Popov; E James Delikatny
Journal:  Prog Lipid Res       Date:  2016-04-09       Impact factor: 16.195

10.  Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy.

Authors:  Elke Hattingen; Oliver Bähr; Johannes Rieger; Stella Blasel; Joachim Steinbach; Ulrich Pilatus
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.